Atypical Posterior Reversible Encephalopathy Syndrome due to Oral Tyrosine Kinase Inhibitor Cabozantinib: First Case Report

We report here a rare case of atypical posterior reversible encephalopathy syndrome (PRES) due to oral tyrosine kinase inhibitor cabozantinib. No case reports of such have been found in our literature search. The patient, a 70-year-old female with metastatic renal cell cancer on oral tyrosine kinase...

Descripción completa

Detalles Bibliográficos
Autores principales: Patwari, Anannya, Bhatlapenumarthi, Vineel, Pascual, Sheila K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506375/
https://www.ncbi.nlm.nih.gov/pubmed/32999665
http://dx.doi.org/10.1159/000509640

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506375/
https://www.ncbi.nlm.nih.gov/pubmed/32999665
http://dx.doi.org/10.1159/000509640

Ejemplares similares